Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC Alkermes.

announced the initiation of a multidose phase 1 clinical study of today ALKS 37, an active orally, peripherally-restricted opioid antagonist with potential to block the consequences of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation . The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in 24 healthy volunteers approximately. Elliot Ehrich, Chief Medical Officer of Alkermes. These outcomes will support a phase 2 clinical study of ALKS 37, that may assess the safety, efficacy and tolerability of ALKS 37 in people with OIC.For the China National Diabetes and Metabolic Disorders Study Group: Prevalence of Diabetes among Women and men in China Cardiovascular disease is among the most leading cause of death in China, a development which has followed rapid economic growth, an increase in life expectancy, and lifestyle changes.1 Diabetes is a significant risk factor for cardiovascular disease, and the prevalence of diabetes is is and high increasing in China.2-4 A national study conducted in 1994, involving 224,251 Chinese residents, 25 to 64 years, from 19 provinces, showed that the prevalences of diabetes and impaired glucose tolerance were 2.5 percent and 3.2 percent, respectively.2 These estimates were higher by a factor of around 3 than those reported in 1980.5 percent and 7.3 percent, respectively.4 Although these studies have got documented a marked upsurge in the prevalence of diabetes in China, they cannot be compared directly, owing to methodologic variations in sampling and to variations in the requirements used to define diabetes.2-4 Furthermore, the prevalences of diabetes and prediabetes were probably underestimated in these research because 2-hour oral glucose-tolerance tests weren’t performed in every participants.